Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Curr Probl Pediatr Adolesc Health Care ; 51(5): 100996, 2021 May.
Article in English | MEDLINE | ID: mdl-34092514

ABSTRACT

The long-standing use of hypotonic fluids in pediatric maintenance fluids has been challenged in recent years due to concerns over iatrogenic hyponatremia causing morbidity and mortality. Newer research has highlighted the safety of isotonic fluid alternatives. The American Academy of Pediatrics published an evidenced-based Clinical Practice Guideline in December of 2018 (Feld et al., 2018) to support the routine use of isotonic solutions in pediatric maintenance fluids. This article will also highlight relevant history, current practice, and a quality improvement project to standardize isotonic fluid use in the inpatient pediatric setting.


Subject(s)
Pediatrics , Quality Improvement , Child , Fluid Therapy , Humans , Hypotonic Solutions , Infusions, Intravenous
2.
J Perinatol ; 39(12): 1648-1655, 2019 12.
Article in English | MEDLINE | ID: mdl-31554913

ABSTRACT

OBJECTIVE: To demonstrate the association between the duration of significant patent ductus arteriosus (PDA) and bronchopulmonary dysplasia (BPD) in extremely preterm infants. METHODS: All extremely preterm infants (<29 weeks) treated in our Neonatal Intensive Care Unit from January 2013 to March 2016 were included if their PDA status was confirmed at <7 days of life. Infants with genetic syndromes, complex congenital anomalies and insignificant PDAs were excluded. Total duration of significant PDA was estimated by reviewing serial echocardiograms. Significant PDA was diagnosed using our scoring system that was based upon echocardiographic parameters and clinical status of the infants. Study cohort was divided into four groups based on the duration of significant PDA. Group A-No PDA, Group B-PDA <1-week, Group C- PDA 1-2 weeks, and Group D-PDA >2 weeks. ANOVA and multivariate analysis were performed to compare the groups. RESULTS: There were 147 infants with no PDA (Group A), 50, 35, and 41 infants were enrolled in Groups B, C, and D, respectively. There were no differences in maternal and neonatal variables among groups except for the following: maternal smoking, chorioamnionitis, antenatal indomethacin, gestation, birth weight, mode of delivery and incidence of death or BPD. Logistic regression analysis showed that longer duration of significant PDA was associated with higher risk for death or BPD (adjusted OR 1.37, 95% CI 1.03-1.82). CONCLUSION: Longer duration of significant PDA is associated with the higher risk for BPD/death in extremely preterm infants.


Subject(s)
Bronchopulmonary Dysplasia/etiology , Ductus Arteriosus, Patent/complications , Infant, Extremely Premature , Infant, Premature, Diseases , Ductus Arteriosus, Patent/mortality , Female , Humans , Infant, Newborn , Infant, Premature, Diseases/mortality , Logistic Models , Male , Multivariate Analysis , Retrospective Studies , Risk Factors , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL